Posted by Michael Wonder on 21 May 2022
Bonesupport receives market authorisation for Cerement G in the US
18 May 2022 - BoneSupport today announced that the company has received market authorisation from the U.S. FDA, for the company's antibiotic eluting product Cerament G, for the indication bone infection (osteomyelitis).
Cerament G has received market authorisation through a de novo process, which is one of the regulatory pathways available when there is no previous comparable product (“predicate device”) legally marketed.
